Charles Zhu
Stock Analyst at LifeSci Capital
(2.78)
# 1,907
Out of 4,955 analysts
25
Total ratings
54.55%
Success rate
21.98%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Charles Zhu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CBIO Crescent Biopharma | Initiates: Outperform | $22 | $13.80 | +59.42% | 1 | Jun 18, 2025 | |
| RPTX Repare Therapeutics | Downgrades: Market Perform | n/a | $1.54 | - | 1 | Dec 13, 2024 | |
| TNGX Tango Therapeutics | Maintains: Buy | $18 → $8 | $6.75 | +18.52% | 3 | Nov 7, 2024 | |
| MGNX MacroGenics | Upgrades: Buy | $12 | $1.49 | +705.37% | 4 | Nov 7, 2023 | |
| MRUS Merus | Maintains: Buy | $46 → $48 | $64.43 | -25.50% | 6 | Aug 8, 2023 | |
| NUVL Nuvalent | Initiates: Buy | $56 | $73.24 | -23.54% | 1 | Jul 24, 2023 | |
| TARA Protara Therapeutics | Assumes: Buy | $22 | $3.03 | +626.07% | 1 | Jul 10, 2023 | |
| COGT Cogent Biosciences | Reiterates: Buy | $26 | $11.87 | +119.13% | 3 | Jun 13, 2023 | |
| IDYA IDEAYA Biosciences | Reiterates: Buy | $32 | $24.32 | +31.58% | 3 | Mar 8, 2023 | |
| ZYME Zymeworks | Upgrades: Buy | $14 | $14.32 | -2.23% | 2 | May 5, 2022 |
Crescent Biopharma
Jun 18, 2025
Initiates: Outperform
Price Target: $22
Current: $13.80
Upside: +59.42%
Repare Therapeutics
Dec 13, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $1.54
Upside: -
Tango Therapeutics
Nov 7, 2024
Maintains: Buy
Price Target: $18 → $8
Current: $6.75
Upside: +18.52%
MacroGenics
Nov 7, 2023
Upgrades: Buy
Price Target: $12
Current: $1.49
Upside: +705.37%
Merus
Aug 8, 2023
Maintains: Buy
Price Target: $46 → $48
Current: $64.43
Upside: -25.50%
Nuvalent
Jul 24, 2023
Initiates: Buy
Price Target: $56
Current: $73.24
Upside: -23.54%
Protara Therapeutics
Jul 10, 2023
Assumes: Buy
Price Target: $22
Current: $3.03
Upside: +626.07%
Cogent Biosciences
Jun 13, 2023
Reiterates: Buy
Price Target: $26
Current: $11.87
Upside: +119.13%
IDEAYA Biosciences
Mar 8, 2023
Reiterates: Buy
Price Target: $32
Current: $24.32
Upside: +31.58%
Zymeworks
May 5, 2022
Upgrades: Buy
Price Target: $14
Current: $14.32
Upside: -2.23%